Skip to main content
BioCentury
As published for the week of Monday, June 20, 2016


  • Cover Story: Fireside with Califf

    FDA Commissioner Califf's priorities on patients, communication and FDA staffing

    By Steve Usdin, Washington Editor

    Three months into his tenure as FDA Commissioner, and less than six months ahead of an election that could start the transition to his successor, Robert Califf is making progress on must-do priorities and trying to advance some big picture goals. Must-do items include finalizing renegotiation of PDUFA, meeting legal requirements for determining how FDA will regulate tobacco products and implementing the Food Safety Modernization Act.

    In a fireside chat with BioCentury at the BIO International Convention, Califf discussed progress on several priorities for drug regulation, including addressing a mismatch between FDA's decades-old policies on regulation of speech about off-label uses of approved medical products, and contemporary judicial interpretations of free speech protections under the First Amendment of the U.S. Constitution.

    Full Article

Money Raised in 2016

Last week, the biotech industry raised $566 million, bringing to $15.8 billion the total raised year-to-date. In 2015, a total of $108.8 billion was raised, including $54.8 billion in debt, $29.6 billion in follow-ons, $3.7 billion in PIPEs and other equity, $8.1 billion in IPOs, and $12.6 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial